Progress in medicinal chemistry

Type Book

Rate 0.0 /5

Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems, including g-secretase modulators, P2X7 antagonists as therapeutic agents for CNS disorders, N-type calcium channel modulators for the treatment …

Details

Files

Reviews

Download

Title Statements

Full title :Progress in medicinal chemistry / edited by G. Lawton, David R. Witty.

Summary

Edition Statements

Publication Date:©2015
Edition:First edition

Publication Statements

Publisher(s):Elsevier
Place of Publication:Amsterdam, Netherlands
Language:eng
Publication Date:©2015

The Physical Object

Description:1 online resource (314 pages) : : illustrations

Edition Identifiers

ISBN:9780444634856, 0444634851, 9780444637154, 044463715X
oclc:ocn905861878
LC Classification:RS403
Dewey Decimal:615.19

Front Cover; Progress in Medicinal Chemistry; Copyright; Contents; Contributors; Preface; Chapter 1: Recent Advances in Cancer Therapeutics; 1. Introduction; 2. Chaperone Inhibitors; 3. Kinase Inhibitors; 3.1. Introduction; 3.2. Vemurafenib-An Inhibitor Targeting a Mutated Kinase; 3.3. Ibrutinib-A Covalent, Irreversible Inhibitor; 3.4. Tumour Resistance to Kinase Inhibitors; 4. HDAC Inhibitors; 4.1. Introduction to Histone Deacetylases; 4.2. Histone Deacetylase Inhibitors; 4.2.1. Biological Activity; 4.2.2. Hydroxamic Acids; 4.2.3. Cyclic Tetrapeptides; 4.2.4. Benzamides.

4.2.5. Aliphatic Acids4.2.6. HDAC Class-Selective Inhibitors; 4.2.7. Histone Deacetylase Inhibitors as Part of Single Agent Therapies; 4.2.8. Histone Deacetylase Inhibitors as Part of Combinatorial Therapies; 5. Inhibitors of Protein-Protein Interactions (PPIs); 5.1. Background; 5.2. BCL-2/BH3-Domain Small-Molecule Inhibitors; 5.3. Inhibiting P53/MDM2 Interaction; 5.4. Rapalogs as Allosteric PPI Inhibitors; References; Chapter 2: Fluorine in Medicinal Chemistry; 1. Introduction; 2. Survey of Fluorine Chemotypes in Marketed Drugs; 3. Impact of Fluorine on Lipophilicity; 3.1. Aromatic Systems.

3.2. Aliphatic Syst…